Michael Burgess
About Michael Burgess
Michael Burgess is the Vice President of Early Clinical Development, Immuno-Oncology and Cell Therapy at Bristol Myers Squibb and an Assistant Clinical Professor at UCSF, with extensive experience in hematology and oncology.
Title and Current Role
Michael Burgess is the Vice President of Early Clinical Development, Immuno-Oncology and Cell Therapy at Bristol Myers Squibb in San Francisco, California. In this role, he leads the development of novel immuno-oncology therapies, contributing to advancements in cancer treatment.
Professional Background
Michael Burgess has held multiple positions within the biotech and pharmaceutical industries. He was previously the Executive Director of Early Clinical Development, Immuno-Oncology and Cell Therapy at Bristol Myers Squibb from 2019 to 2020. Before that, he worked at Celgene, starting as Director of Translational Medicine, Hematology/Oncology and later becoming Senior Director and Executive Director in the same field.
Academic Roles and Contributions
Michael Burgess is currently serving as an Assistant Clinical Professor in Hematology/Oncology at UCSF. He has been actively involved in mentoring and training the next generation of oncologists and clinical researchers. He previously served as a Clinical Instructor and Clinical Fellow at UCSF, emphasizing his commitment to both education and clinical practice.
Education and Expertise
Michael Burgess holds a PhD from the University of California, Los Angeles, completed from 2000 to 2005, and an MD from the David Geffen School of Medicine at UCLA, completed from 1998 to 2007. He also holds a BA from the University of California, Berkeley, completed from 1994 to 1997. His extensive education has equipped him with a deep understanding of translational medicine, particularly in hematology and oncology.
Industry and Clinical Trials Experience
Michael Burgess has a strong background in both academic and industry settings, providing a unique perspective on the integration of scientific research and clinical practice. He has played a key role in the early clinical development of cellular therapies aimed at treating various forms of cancer, bridging the gap between laboratory research and clinical application.